Portfolio Companies

Summary

Sonorous is developing a vascular stent device to be placed into the cerebral sinuses of patients with intrinsic or extrinsic stenosis which causes pulsatile tinnitus (PT). PT is caused by a venous sinus stenosis/stiffening causing hemodynamic turbulent blood flow and high frequency

turbulence transmitted to the inner ear as a pulsating sound. Sonorous’ vascular stent opens the narrowed vessel and restores blood flow.

Documents

Sonorous Series A and Investor Update – Q1 2024

Website

https://www.sonorousnv.com/

Summary

Hilltop Bio makes advanced regenerative therapies that have been tailored for practical applications in veterinary practices. They stimulate cell-to-cell communication that is essential for healing by delivering an intracellular, cell-signaling cascade of cytokines, growth factors, and exosomes that accelerates tissue repair and establishes normal tissue functionality.

Documents

Hilltop Investor Update Q4 2023

Hilltop Bio Supports the EQUUS Foundation with Veterinary Scholarship and Product Donation – 17 Nov 2023

Hilltop Bio Supports Not One More Vet with Donations per Product Purchased Donations – 6 Nov 2023

Hilltop Bio Investor Update Q3 2023

[ Read more… ]

Summary

TSSC’s 3D technology can significantly improve device navigation and localization, resulting in safer, faster, and more effective surgical procedures, therefore enabling better patient outcomes, the ultimate goal of medicine.

Documents

The Shape Sensing Company – 2024 Q1 Update

The Shape Sensing Company – 2023 Q4 Update

The Shape Sensing Company – Update 2023 Q1

MABA Invests in 3D Shape Sensing Technology

Website https://shapesensing.com/

Summary

Developing digital twin of cells for drug discovery.

Documents

Deep Life Investor Update Q3 2023

Deep Life Investor Update April 2023

DeepLife Investor Update Oct 2022

MABA Announces First Foray into Digital Health with Investment in Biotech Company DeepLife

Website https://www.deeplife.co/

Summary

Developing a pipeline of best-in-class oncolytic immunotherapeutics that are highly effective in treating cancer patients with solid cancers.

Documents

Seneca Therapeutics Investor Update Q1 2024

Seneca Therapeutics Investor Call Deck Q1 2024

Seneca Therapeutics Shareholder Letter Q1 2024

Seneca Investor Update Q4 2023

Seneca-Update-Fall-2022

Seneca Therapeutics Series B Convertible Deck October 2021 v3.2

Seneca Update Fall 2021

Seneca Seasonal_Issue 7_Spring 2021

Seneca Seasonal Issue 6 Winter 2021

Website

https://www.senecatherapeutics.com/ [ Read more… ]

Summary

Novel neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI), concussion, and neurodegenerative diseases.

Documents

Astrocyte Pharmaceuticals – 2024 Q1 Update

Astrocyte Pharmaceuticals – 2023 Q4 Update

Astrocyte Pharmaceuticals 2023 Q2 Update

Astrocyte Pharmaceuticals 2023 Q1 Update

Astrocyte Pharmaceuticals 2022 Q4 Update

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Astrocyte Pharmaceuticals 2022 Q2 Investor Update

Astrocyte Pharmaceuticals 2022 Q1 Investor Update

Astrocyte Pharmaceuticals 2021 Q4 Investor Update

Summary

A mesh-free approach for pelvic floor fixation for Pelvic Organ Prolapse (POP), which is a painful, debilitating medical condition that occurs when the normal support of the vagina is lost, resulting in the “sagging” or dropping of the female pelvic organs.

Documents

FEMSelect Update and Convertible Note Financing Term Sheet Q1 2024

FEMSelect Investor Update Q3 2023

FEMSelect 2023 Q2 Investor Update – Video

Dec 16, 2021 Investor Call – 2021 Q4 Investor Update presentation v4 FINAL (slides). Link to presentation.

2021 Q3 Investor Update FINAL

LiNA Medical USA and FEMSelect Announce National [ Read more… ]

Summary

New View Surgical – novel VisionPort™ System is the first surgeon-controlled, multi-camera laparoscopic visualization system.

Documents

New View Surgical Shareholder Election Results – Plan for Dissolution Passes April 3, 2024

New View Surgical Update (2023-07-21)

New View Surgical Q1 2023 Update

New View Surgical – Investor Update Webinar

New View Surgical FY 2022 Update

New View Surgical Q4 2022 Update

New View Surgical Q3 2022 Update

New View Surgical 2022 Q2 Update

New View Surgical 2022 Q1 Financial Statements and Management Notes

New View Surgical 2022 [ Read more… ]

Summary

Healionics is a clinical stage company addressing the critical need for improved means of dialysis access in patients with kidney failure. Healionics’ STARgraft vascular graft (artificial blood vessel) resists the problems of occlusion and infection suffered by current devices. The company is also developing a product pipeline based on its platform STAR® biomaterial, which has a unique ability to prevent both scarring and infection in a wide variety of other implantable device applications.

Documents

Healionics Q4 2023 Update

Healionics Q3 2023 Update

Healionics Q2 2023 Update

Healionics 2023 Q1 Update

Healionics [ Read more… ]

Summary

Elysium’s O2P (oral overdose protection) technology addresses multiple epidemics – prescription drug abuse, overdose, and undertreated pain.

Documents

Elysium Milestone Update 3.5.2024

Elysium Investor Update Q1 2024

Elysium Investor Update Q3 2023

Elysium Investor Update (2023-07-18)

Elysium Update 2022 Q4

Elysium Update 2022 Q2

Elysium Update Jan 2022

Elysium Update 2021 Q2

Elysium Update 2020 Q4

Elysium Update 2020 Q3

Elysium Update 2020 Q1

Elysium Investor Deck 3/2019

Elysium Update 2018 Q3

Website https://www.elysiumrx.com/ [ Read more… ]